PYC Therapeutics Says Safety Review Committee Approves Dose Escalation to Final Patient Group in Eye Disease Study; Shares Down 3%
PYC Therapeutics Says Safety Review Committee Approves Dose Escalation to Final Patient Group in Eye Disease Study; Shares Down 3%
PYC Therapeutics表示，安全審查委員會批准將眼部疾病研究的劑量逐步增加至最終患者群體；股價下跌3%。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間